Lab Wants DEA Nod to Import Marijuana as Controlled Substance
Published Date: 4/18/2025
Notice
Summary
Scottsdale Research Institute wants to become an official importer of certain controlled substances, including marijuana. People and companies involved with these drugs can share their thoughts or ask for a hearing by May 19, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Schedule I Synthetic Cannabidiol
On January 13, 2025 Scottsdale Research Institute applied to register as an importer of Marihuana (drug code 7360, Schedule I). The company plans to import a synthetic cannabidiol as an active pharmaceutical ingredient for clinical research by Schedule I registrants. Stakeholders may submit comments or request a hearing on or before May 19, 2025.
Import Restricted to APIs — No Finished Products
The requested registration would authorize import only of active pharmaceutical ingredients for research and specifically states that "no other activity for this drug code is authorized". Authorization will not extend to the import of FDA-approved or non‑approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20757, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06704, 2025 Terrorism Risk Insurance Program Data Call
If you’re an insurer selling commercial property or casualty insurance, the 2025 Terrorism Risk Insurance Program Data Call wants your info on 2024 policies by May 15, 2025. This helps the government keep terrorism insurance available and affordable. You’ll register online, fill out forms, and submit data securely—no surprises, just smooth reporting!
Next: 2025-06706, Bulk Manufacturer of Controlled Substances Application: Stepan Company
Stepan Company wants to get official permission to make large amounts of cocaine and ecgonine, which are controlled substances. This affects other manufacturers and the public, who can share their thoughts or ask for a hearing by June 17, 2025. The company will use these substances mainly to make other products or sell to customers, with no extra activities allowed.